Royalty Pharma’s Earnings Call Signals Confident Growth

Royalty Pharma PLC ((RPRX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Royalty Pharma struck an upbeat tone on its latest earnings call, highlighting double‑digit recurring revenue growth and strong cash generation despite some headwinds. Management emphasized attractive returns on capital, a fortified balance sheet, and a deep pipeline of royalty opportunities, arguing that raised guidance and robust deal activity more than offset pressures from lower milestones and higher interest costs.

Top-line and Recurring Cash Flow Growth

Portfolio receipts rose 10% in Q1, while recurring royalty receipts climbed 13% year over year on the back of Tremfya, Voranigo and Evrysdi. The company still posted double‑digit royalty growth despite a roughly 3% drag from Promacta’s loss of exclusivity, underlining the resilience and diversification of its portfolio.

Attractive Returns and Cash Generation

Royalty Pharma reported a last‑twelve‑month return on invested capital of about 14.1% and return on invested equity near 19.7%. Portfolio cash flow reached $722 million in Q1, with a roughly 78% net margin, underscoring the high cash conversion of its royalty model and supporting continued reinvestment and shareholder returns.

Active Capital Deployment and Shareholder Returns

The company announced $1.25 billion of transactions across three therapies and deployed $528 million of capital during the quarter. It also repurchased 1 million shares for $50 million and lifted its dividend by 7%, signaling confidence in long‑term cash flows and a balanced commitment to growth and capital return.

Strategic Acquisitions with Blockbuster Potential

A key move was the purchase of a 30% slice of Ziihera royalties for $250 million, equating to a low‑ to mid‑single‑digit royalty interest. With Ziihera filed in gastric cancer and consensus expectations for peak sales above $2 billion, management expects the deal to generate a low double‑digit unlevered internal rate of return.

Major Clinical and Regulatory Wins

Royalty Pharma highlighted several pipeline catalysts, led by Revolution Medicines’ daraxonrasib, where Phase III data nearly doubled overall survival in second‑line pancreatic cancer to more than 13 months. Additional validation came from FDA approval of Denali’s Avlayah and positive pivotal or Phase II results for assets like Myqorzo, obexelimab, litifilimab and neladalkib, supporting future royalty streams.

R&D Co-funding Momentum and New Market Opportunity

The quarter showcased growing traction in R&D co‑funding, with new deals with J&J and Teva totaling about $1 billion in announced value. Since 2022 the company has now signed five such agreements with up to $1.8 billion of potential commitments, positioning it to tap into more than $1 trillion of expected global biopharma R&D spend over the next five years.

Balance Sheet Strength and Financial Flexibility

Royalty Pharma closed Q1 with $586 million in cash and equivalents, $9.2 billion of investment‑grade debt and an undrawn $1.8 billion revolver. Fitch upgraded its rating to BBB, leverage stood at roughly 2.9x total debt to adjusted EBITDA (2.7x net), and management estimates around $4 billion of financial flexibility to fund future transactions.

Operational Efficiency Gains

Operating and professional costs were 3.9% of portfolio receipts in Q1, benefiting from internalization efforts and a scalable platform. For the full year, management expects these expenses to run about 5.5% to 6.5% of portfolio receipts, still indicating a lean cost structure that should support margins as the business grows.

Decline in Milestones and Other Contractual Receipts

A key offset to royalty growth is a sharp decline in milestones and other contractual receipts, which fell year over year and are set to compress further. Management projects these payments will drop from $128 million in 2025 to roughly $60 million in 2026, a decline of about 53%, moderating overall portfolio receipts growth versus recurring royalties.

Interest Expense and Timing Pressure

Net interest paid reached $167 million in Q1, reflecting semiannual payment timing that can distort quarterly cash flows. For 2026, management expects total interest paid of about $350 million to $360 million, with a heavy concentration around Q3 and minimal payments in Q2 and Q4, making cash flow seasonality an important consideration for investors.

Market and Policy Headwinds

The portfolio faces some external pressures, including a roughly 3% drag on royalty receipts from Promacta’s loss of exclusivity and the U.S. launch of a biosimilar to Tysabri. Management also flagged uncertainty from pricing reforms and policy changes abroad, which complicate forecasting for international launches and could weigh on future royalty ramps.

Execution and Optionality Risks in Co-funding Structure

While R&D co‑funding is a growing pillar, several funding tranches remain at partners’ option, creating potential execution risk around future capital calls. Co‑funding has historically been a smaller share of activity, so scaling this strategy will test Royalty Pharma’s ability to manage complex structures while maintaining attractive risk‑adjusted returns.

Arbitration Timing Delay

The ongoing arbitration with Vertex has now been pushed back, with resolution not expected until around mid‑2027 due to panel availability. This extension prolongs uncertainty around the dispute and any potential financial impact, though management did not indicate a change to near‑term operating plans as a result.

Guidance and Forward-looking Outlook

Management raised its 2026 portfolio receipts guidance to $3.325 billion–$3.45 billion and now expects royalty receipts to rise about 4%–8%, with Q2 portfolio receipts guided to $740 million–$760 million. While milestones are set to fall and annual interest paid should land near $350 million–$360 million, the company anticipates operating costs at 5.5%–6.5% of receipts and sees ample balance sheet capacity to keep funding growth and shareholder returns.

Royalty Pharma’s call painted a picture of a high‑margin, cash‑rich business leaning into new royalty and co‑funding opportunities while managing identifiable risks. With recurring royalties growing, guidance moving higher and financial firepower intact, the company is positioning itself as a durable way to gain exposure to late‑stage and commercial biopharma assets, even as policy, interest and execution risks remain on the radar.